CymaBay Appears Stronger Threat To Ocaliva In PBC Than Ipsen/Genfit

 
• By Joseph Haas
  
2023 AASLD
PPAR agonists from Genfit and CymaBay are battling for a second-line indication in PBC • Source: Scrip
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business